European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): A randomized trial

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 5, 1997, Pages 473-478

  Landolfi, Raffaele ^a   Marchioli, Roberto ^b  

^a Ist Semeiot Medica Univ C   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Aspirin; ECLAP trial; Low dose ASA; Polycythemia vera; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESEARCH; DRUG SCREENING; EUROPE; FOLLOW UP; HUMAN; INTERNATIONAL COOPERATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS;

EID: 0030856125     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996124     Document Type: Article

References (19)

1. Antiplalelet Trialists' Collaboration: Collaborative overview of randomized trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308: 81-106, 1994.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 308:235-246, 1994.
3. Barabas AP, DN Offen, EA Meinhard: The arterial complications of polycythaemia vera. Br J Surg 60:183-187, 1973.
4. Pearson TC, G Wetherley-Mein: Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 2:1219-1222, 1978.
5. Tartaglia A, J Goldberg, P Berk, et al: Adverse effects of antiaggregating platelet therapy in the treatment of polycythaemia vera. Semin Hematol 23:172-176, 1986.
6. Egli F. A Wieczorek, M Niemoeller: Polycythaemia vera: Klinik und Verlauf bei 86 Patienten. Schweiz Med Wochenschr 118: 1969-1975, 1988.
7. Gilbert HS, MM Hanna: Low-dose aspirin/low hematocrit regimen: A safe and efficacious treatment for polycythaemia vera. Blood 68:770a, (Abstr), 1986.
8. Fröhli P, C Graf, K Rhyner: Die Prophylaxe vaskulärer Komplikationen bei Polycythaemia vera und primärer Thrombozythmie mit niedrig dosierter Acetylsalicyls. Schweiz Med Wochenschr 113:1622-1627, 1983.
9. The RISC Group: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336:827-830, 1990.
10. The SALT Collaborative Group: Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 338: 1345-1349, 1991.
11. The Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients alter a transient ischemic attack or minor ischemic stroke. N Engl J Med 325: 1261-1266, 1991.
12. Michiels J, J Abels, J Steketee, et al: Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 102:466-471, 1985.
13. Scheffer MG, JJ Michiels, ML Simoons, et al: Thrombocythemia and coronary artery disease. Am Heart J 122:573-576, 1991.
14. Michiels J, P Koudstaal, A Mulder, et al: Transient neurologic and ocular manifestation in primary thrombocythemia. Neurology 43:1107-1110, 1993.
15. Landolfi R, G Ciabattoni, P Patrignani, et al: Increased thromboxane biosynthesis in patients with polycythaemia vera: Evidence for aspirin-suppressible platelet activation in vivo. Blood 80:1965-1971, 1992.
16. Rocca B, G Ciabattoni, R Tartaglione, et al: Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemostas 74:1225-1230, 1995.
17. Gruppo Italiano Studio Policitemia Vera: Polycythaemia vera: The natural history of 1213 patients followed over 20 years. Ann Intern Med 123:656-664, 1995.
18. Gruppo Italiano Studio Policitemia Vera: Low-dose aspirin in polycythaemia vera. A pilot study. Br J Haematol 97:453-456, 1997.
19. ISIS-3 (Third International Study of Infarct Survival Collaborative Group). ISIS-3: A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin and heparin vs heparin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 339:753-777, 1992.